Loading people...
Luciana Borio is a Venture Partner at ARCH Venture Partners and a Senior Fellow for Global Health at the Council on Foreign Relations. Prior to joining ARCH in 2021, she served as a Vice President at In-Q-Tel from 2019 to 2021 and as the Director for Medical and Biodefense Preparedness Policy at the National Security Council from 2017 to 2019. She holds an MD from George Washington University, and her public sector experience includes serving as the Assistant Commissioner for Counterterrorism Policy at the FDA. Borio currently serves on the board of directors for Insulet Corporation and Eagle Pharmaceuticals, while maintaining an academic appointment as adjunct faculty at the Johns Hopkins University School of Medicine. As an infectious disease physician and public health expert, her professional focus centers on biodefense, emerging infectious diseases, and advancing medical product development.
Luciana Borio is a distinguished Venture Partner at ARCH Venture Partners, bringing an unparalleled depth of expertise in public health, biodefense, and regulatory science to the firm's pioneering investments. At ARCH, a leading venture capital firm renowned for its focus on early-stage deep technology and life science companies, Dr. Borio plays a pivotal role in identifying and nurturing groundbreaking ventures that address critical global health and security challenges.
Her investment focus at ARCH is strategically aligned with her extensive career background. Dr. Borio is particularly interested in companies developing innovative solutions in areas such as biodefense, pandemic preparedness, medical countermeasures, and emerging infectious diseases. This includes therapeutics, vaccines, diagnostics, and platform technologies designed to enhance national and global health security. Her unique perspective, honed through years of high-level government service, allows her to identify promising technologies with significant impact potential and navigate complex regulatory landscapes.
Before joining ARCH Venture Partners, Dr. Borio held several influential positions that shaped her expertise. A physician by training, she served as the Special Assistant to the President and Deputy Assistant to the President for Biodefense Policy at the National Security Council (NSC) during the Trump administration. In this critical role, she was instrumental in developing and implementing national biodefense strategies, ensuring the nation's readiness against biological threats.
Prior to her tenure at the NSC, Dr. Borio made significant contributions at the U.S. Food and Drug Administration (FDA). She served as the Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy, where she played a key role in advancing medical product development for chemical, biological, radiological, and nuclear threats. Her work at the FDA involved overseeing scientific initiatives and policy development related to public health emergencies and regulatory science, giving her invaluable insight into the challenges and opportunities within the life sciences sector.
At ARCH Venture Partners, Luciana Borio leverages this rich experience to guide investments in companies poised to make a substantial difference. She helps ARCH identify and build companies that not only offer innovative scientific solutions but also possess the potential for real-world impact in safeguarding public health. Her involvement underscores ARCH's commitment to backing visionary entrepreneurs who are tackling some of humanity's most pressing health and security issues, from preventing future pandemics to developing advanced medical technologies for critical care. Her strategic insights are invaluable in shaping the next generation of life science leaders.
Luciana Borio is a physician and a prominent expert in public health and biodefense, currently serving as a Venture Partner at ARCH Venture Partners. She held key leadership roles at the FDA and the National Security Council, advising on biodefense policy and medical countermeasures.
Luciana Borio focuses on investments in life sciences, particularly in areas related to biodefense, pandemic preparedness, medical countermeasures, and emerging infectious diseases. Her work at ARCH Venture Partners supports companies developing innovative solutions for global health security.
Luciana Borio works as a Venture Partner at ARCH Venture Partners, a leading venture capital firm known for its investments in early-stage deep technology and life science companies.
